Cart (0 Items)
Your cart is currently empty.
View ProductsBrand | ProteoGenix |
---|---|
Product type | Elisa assay kits |
Size | 96T |
Product name | Figitumumab ELISA Kit |
---|---|
Delivery condition | Blue ice (+4°) |
Storage condition | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
Brand | ProteoGenix |
Size | 96T |
Reference | KPTX159 |
Note | For research use only. |
Sample type | Plasma, Serum |
Immunogen | Figitumumab |
The Figitumumab ELISA Kit is a highly sensitive and specific assay used for the detection and quantification of Figitumumab, a monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R). This kit is designed for use in various biological samples, including serum, plasma, and cell culture supernatants. The development of this ELISA kit has greatly aided in the research and development of Figitumumab as a potential therapeutic agent for various diseases.
Figitumumab is a fully human monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of Figitumumab is responsible for its high specificity and affinity for the IGF-1R.
The IGF-1R is a transmembrane receptor that plays a crucial role in cell growth and survival. It is a tyrosine kinase receptor, meaning it can activate various signaling pathways upon binding to its ligands, insulin-like growth factor 1 (IGF-1) and insulin-like growth factor 2 (IGF-2). Figitumumab specifically targets the extracellular domain of the IGF-1R, preventing the binding of IGF-1 and IGF-2 and inhibiting downstream signaling pathways.
The main activity of Figitumumab is its ability to block the activation of the IGF-1R and inhibit downstream signaling pathways. This leads to the inhibition of cell growth and survival, making Figitumumab a potential therapeutic agent for various diseases characterized by abnormal cell growth, such as cancer.
Research has shown that Figitumumab can induce cell cycle arrest and apoptosis in cancer cells that overexpress the IGF-1R. It has also been shown to enhance the effects of chemotherapy and radiation therapy in cancer treatment. In addition, Figitumumab has shown promising results in preclinical studies for the treatment of other diseases, such as type 2 diabetes and acromegaly.
The Figitumumab ELISA Kit is a valuable tool for the detection and quantification of Figitumumab in biological samples. It is widely used in research and clinical studies to monitor Figitumumab levels in patients receiving treatment with this antibody. The kit can also be used to assess the pharmacokinetics of Figitumumab, allowing researchers to determine the optimal dosage and dosing schedule for maximum efficacy.
In addition, the Figitumumab ELISA Kit can be used to screen for potential biomarkers that may predict the response to Figitumumab treatment. This can aid in patient selection and personalized treatment strategies for improved outcomes.
The Figitumumab ELISA Kit is a powerful tool for the detection and quantification of Figitumumab, a monoclonal antibody that targets the IGF-1R. Its high sensitivity and specificity make it an essential assay for the development and evaluation of Figitumumab as a potential therapeutic agent for various diseases. With its wide range of applications, the Figitumumab ELISA Kit continues to play a crucial role in advancing research and improving patient outcomes.
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.